BeiGene, Ltd.
NASDAQ: BGNE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John V. Oyler
- Employees
- 10,600
- Headquarters
- Cambridge, United States
- IPO year
- 2016
- Market cap
- $20.2B
- Website
- https://www.beigene.com
Loading BGNE…
Loading profile data…Frequently asked questions about BGNE
What does BeiGene, Ltd. (BGNE) do?
BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for rel...
Where does BGNE trade?
BeiGene, Ltd. (BGNE) trades on the NASDAQ Global Select.
What sector is BGNE in?
BeiGene, Ltd. (BGNE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BeiGene, Ltd.?
John V. Oyler is the chief executive officer of BeiGene, Ltd. (BGNE).
Where is BeiGene, Ltd. headquartered?
BeiGene, Ltd. is headquartered in United States.
Does BGNE pay a dividend?
BeiGene, Ltd. (BGNE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BGNE go public?
BeiGene, Ltd. (BGNE) completed its initial public offering in 2016.
Is BGNE an ADR?
Yes — BGNE is an American Depositary Receipt; its underlying shares trade on a non-US exchange. BeiGene, Ltd. reporting and dividends follow the underlying issuer.